Zydus Lifesciences Clarifies No Material Impact from Delhi HC Order

Zydus Lifesciences Ltd has responded to a clarification sought by BSE Limited regarding a news item about a Delhi High Court order temporarily restricting the supply of its cancer drug IkraTM. The company stated that there are no ongoing negotiations or events requiring disclosure under SEBI regulations. Furthermore, Zydus clarified that the said event is not material according to their policy and the Listing Regulations. They also confirmed that the news did not cause any material movement in the trading of their equity shares on July 14, 2026, and they believe there is no material impact on the company. Zydus remains committed to compliance with disclosure requirements.